Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidrad… Read more
Kymera Therapeutics Inc (KYMR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.029x
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has a cash flow conversion efficiency ratio of -0.029x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.11 Million) by net assets ($946.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Kymera Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Kymera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Kymera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kymera Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Central Pattana Public Company Limited
PINK:CPNNF
|
0.078x |
|
Structure Therapeutics Inc. American Depositary Shares
NASDAQ:GPCR
|
-0.042x |
|
CCOOP Group Co Ltd
SHE:000564
|
-0.007x |
|
Union Bank of India
NSE:UNIONBANK
|
-0.109x |
|
ICL Israel Chemicals Ltd
NYSE:ICL
|
0.048x |
|
Voltas Limited
NSE:VOLTAS
|
-0.167x |
|
Ondas Holdings Inc.
NASDAQ:ONDS
|
-0.021x |
|
Tokyu Fudosan Holdings Corporation
PINK:TTUUF
|
0.029x |
Annual Cash Flow Conversion Efficiency for Kymera Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Kymera Therapeutics Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $835.62 Million | $-194.50 Million | -0.233x | +10.59% |
| 2023-12-31 | $394.97 Million | $-102.83 Million | -0.260x | +16.64% |
| 2022-12-31 | $490.15 Million | $-153.09 Million | -0.312x | -11.33% |
| 2021-12-31 | $459.64 Million | $-128.95 Million | -0.281x | -190.37% |
| 2020-12-31 | $283.89 Million | $88.13 Million | 0.310x | +229.01% |
| 2019-12-31 | $-74.41 Million | $17.91 Million | -0.241x | -146.39% |
| 2018-12-31 | $-34.44 Million | $-17.86 Million | 0.519x | -- |